An overview of lefamulin for the treatment of community acquired bacterial pneumonia.

Abstract:

INTRODUCTION:Lefamulin is a novel antibiotic that belongs to the pleuromutilin class with excellent activity against all microorganisms, including atypical pathogens, that cause community-acquired pneumonia (CAP). AREAS COVERED:This article reviews the spectrum of activity, the main pharmacokinetic and pharmacodynamic characteristics of lefamulin as well as its clinical efficacy and safety in the treatment of CAP in adult patients. EXPERT OPINION:The clinical efficacy of lefamulin in patients with non severe CAP has been demonstrated in 2 randomized clinical trials. Precisely one of the limitations of the phase 3 trials is that the proportion of severe CAP cases is very low. Its particular mechanism of action, affecting ribosomal protein synthesis, provides a low probability of cross-resistance to other commonly used antibiotics in CAP. These findings, together with the antimicrobial activity of lefamulin, its pharmacokinetic parameters and safety profile make it a good alternative for outpatient treatment of CAP. In patients hospitalized with CAP, lefamulin can be used as a potential oral step-down agent after an intravenous regimen with beta-lactams, or as a therapeutic alternative in patients with β-lactam allergies.

authors

Falcó V,Burgos J,Almirante B

doi

10.1080/14656566.2020.1714592

subject

Has Abstract

pub_date

2020-04-01 00:00:00

pages

629-636

issue

6

eissn

1465-6566

issn

1744-7666

journal_volume

21

pub_type

杂志文章,评审
  • Everolimus: an immunosuppressive agent in transplantation.

    abstract::Everolimus is a novel immunosuppressive agent related to sirolimus. It is a proliferation signal inhibitor with an improved pharmacokinetic profile and bioavailability compared with sirolimus. Everolimus has been shown to be as effective as mycophenolate mofetil in reducing acute rejection in renal transplantation. In...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.10.1347

    authors: Patel JK,Kobashigawa JA

    更新日期:2006-07-01 00:00:00

  • An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.

    abstract:INTRODUCTION:Moderate-to-severe AD burdens a large proportion of AD patients and may represent an inadequacy of treatment options available for resistant disease. AREAS COVERED:This review provides an overview of the therapies for moderate-to-severe AD in late-stage development and in the clinic, and focuses on barici...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,评审

    doi:10.1080/14656566.2020.1739268

    authors: Mendes JT,Balogh EA,Strowd LC,Feldman SR

    更新日期:2020-06-01 00:00:00

  • Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects.

    abstract:INTRODUCTION:Benign prostate hyperplasia (BPH) is one of the most prevalent diseases in aging men. It may adversely affect quality-of-life due to the presence of low urinary tract symptoms (LUTS) and its effects on sexuality. AREAS COVERED:The impact of α1-blockers, 5α-reductase inhibitors (5-ARI), and phosphodiestera...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1817382

    authors: La Vignera S,Aversa A,Cannarella R,Condorelli RA,Duca Y,Russo GI,Calogero AE

    更新日期:2020-09-09 00:00:00

  • New phosphodiesterase inhibitors in the treatment of erectile dysfunction.

    abstract::Sildenafil revolutionised the treatment of erectile dysfunction (ED) on its introduction in 1998. Not only is it effective, but is, perhaps even more importantly, an extremely acceptable manner in which to treat ED (i.e., oral pharmacotherapy), compared to the other treatments that were available at that time (e.g., i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.11.2241

    authors: Anderson PC,Gommersall L,Hayne D,Arya M,Patel HR

    更新日期:2004-11-01 00:00:00

  • Anti-thrombotic therapy in cancer patients.

    abstract::Primary and secondary prevention of venous thromboembolism (VTE) are the major roles of anti-thrombotic therapy in patients with cancer. Although the choices of pharmacological agents remain limited, low molecular weight heparins (LMWHs) offer important advantages over traditional anticoagulants. For prophylaxis in th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.12.2213

    authors: Lee AY

    更新日期:2003-12-01 00:00:00

  • The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin.

    abstract::Gestational diabetes (GD) develops because pregnancy increases requirements for insulin secretion while increasing insulin resistance. Women with GD often have impaired pancreatic beta-cell compensation for insulin resistance. The nature of GD is currently contentious, with debate about its existence, diagnosis and ra...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.11.1557

    authors: Glueck CJ,Goldenberg N,Streicher P,Wang P

    更新日期:2002-11-01 00:00:00

  • A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.

    abstract:INTRODUCTION:Psoriasis is a chronic, inflammatory disease afflicting 2% of the US population; it results in significant morbidity. The annual healthcare costs related to psoriasis are an estimated $11.3 billion and, with an expanding biologic market, an updated costs analysis is needed. AREAS COVERED:Current treatment...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.590475

    authors: Staidle JP,Dabade TS,Feldman SR

    更新日期:2011-09-01 00:00:00

  • Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults.

    abstract:INTRODUCTION:Only 40-60% of obsessive-compulsive patients respond to first line treatments, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy. Several second-line treatments have been investigated in the last two decades, and most of them seem to work, at least in a subset of pati...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1528230

    authors: Grassi G,Pallanti S

    更新日期:2018-10-01 00:00:00

  • The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.

    abstract:BACKGROUND:This study examined the effects of short-term administration of the sodium glucose cotransporter 2 (SGLT-2) inhibitor, dapagliflozin, on visceral fat area (VFA) in Japanese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS:In this randomized, crossover, controlled clinical trial, overweight patient...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14656566.2017.1317748

    authors: Kato K,Suzuki K,Aoki C,Sagara M,Niitani T,Wakamatsu S,Yanagi K,Aso Y

    更新日期:2017-06-01 00:00:00

  • Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.

    abstract:BACKGROUND:Alzheimer's disease is thought to be caused by increased formations of neurotoxic amyloid beta (A beta) peptides, which give rise to the hallmark amyloid plaques. Therefore, pharmacological agents that reduce A beta formation may be of therapeutic benefit. OBJECTIVE:This paper reviews the pharmacology and c...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903044982

    authors: Henley DB,May PC,Dean RA,Siemers ER

    更新日期:2009-07-01 00:00:00

  • Pharmacological management of axial spondyloarthritis in adults.

    abstract::Introduction: Spondyloarthritis (SpA) refers to a group of disorders sharing common clinical, genetic and imaging characteristics. Axial (ax) SpA corresponds to a subgroup that mainly affects the axial skeleton, leading to inflammatory back pain and progressive radiographic changes of the sacroiliac joints and the spi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1617853

    authors: Toussirot E

    更新日期:2019-08-01 00:00:00

  • Delaying surgery with chemotherapy for osteosarcoma of the extremities.

    abstract::Osteosarcoma is the most frequent primary cancer of bone. When treated by surgery alone, it is almost invariably followed by metastatic dissemination and death. This dismal prognosis can be improved dramatically by including chemotherapy in an interdisciplinary regimen. Today, two-thirds of patients with localised ext...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.6.1243

    authors: Bielack SS,Machatschek JN,Flege S,Jürgens H

    更新日期:2004-06-01 00:00:00

  • Treating short bowel syndrome with pharmacotherapy.

    abstract:INTRODUCTION:Short bowel syndrome (SBS) has traditionally been regarded as a rapidly fatal medical catastrophe. The advent of pharmacological options directly targeting disease pathophysiology justified this review. AREAS COVERED:Since the 1970s, home parenteral nutrition has reduced mortality, converting SBS into a c...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1724959

    authors: Hollanda Martins Da Rocha M,Lee ADW,Marin MLM,Faintuch S,Mishaly A,Faintuch J

    更新日期:2020-04-01 00:00:00

  • Synthetic pharmacotherapy for lupus nephritis.

    abstract:INTRODUCTION:Lupus nephritis is a frequent complication and a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Area covered: The main characteristics and mechanisms of action of the synthetic drugs more frequently used in lupus nephritis are described. Possible strategies aime...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1276563

    authors: Moroni G,Ponticelli C

    更新日期:2017-02-01 00:00:00

  • Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts.

    abstract::Introduction: Ventricular arrhythmias are often seen in association with structural heart disease. However, approximately a tenth of affected patients have apparently normal hearts, where such arrhythmias typically occur in young patients, are sometimes inherited and can occasionally lead to sudden cardiac death (SCD)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1669561

    authors: Ortmans S,Daval C,Aguilar M,Compagno P,Cadrin-Tourigny J,Dyrda K,Rivard L,Tadros R

    更新日期:2019-12-01 00:00:00

  • Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer.

    abstract::Developments in the role of adjuvant and neoadjuvant chemotherapy for the treatment of patients with breast cancer have focused on the taxes, in particular, docetaxel. This paper discusses the rationale for the introduction of docetaxel into the management of patients following surgery and also its role in those patie...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.10.2147

    authors: Heys SD,Sarkar T,Hutcheon AW

    更新日期:2004-10-01 00:00:00

  • Exemestane in postmenopausal women with early or advanced breast cancer: a review.

    abstract:IMPORTANCE OF THE FIELD:Inhibition of the aromatase enzyme in postmenopausal women reduces levels of estrogens, which is of therapeutic value in hormone-sensitive breast cancer. Exemestane is a third-generation steroidal irreversible inactivator of the aromatase enzyme used in early and advanced breast cancer for the t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.495945

    authors: Bertelli G,Gangadhara S

    更新日期:2010-08-01 00:00:00

  • Pemetrexed for the treatment of non-small cell lung cancer.

    abstract:INTRODUCTION:Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have become available for the treatment of this disease. Pemetrexed , a multi-target folate antagonist, has improved the survival of non-squamous...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.802774

    authors: Genova C,Rijavec E,Truini A,Coco S,Sini C,Barletta G,Dal Bello MG,Alama A,Savarino G,Pronzato P,Boccardo F,Grossi F

    更新日期:2013-08-01 00:00:00

  • An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.

    abstract:INTRODUCTION:Phosphodiesterase type 5 inhibitors (PDE5-i) are used for the oral treatment of erectile dysfunction (ED). Since the launch of sildenafil more than 15 years ago, new molecules have become available. At present, in addition to tadalafil and vardenafil, there are three other drugs, udenafil, avanafil and mir...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.799665

    authors: Bruzziches R,Francomano D,Gareri P,Lenzi A,Aversa A

    更新日期:2013-07-01 00:00:00

  • Memantine in the treatment of mild-to-moderate Alzheimer's disease.

    abstract::Memantine is the first and only medication that has been approved by European, US and Canadian regulatory agencies for the treatment of moderate-to-severe Alzheimer's disease (AD). It is an NMDA receptor antagonist that works to prevent excitotoxicity and cell death, which are mediated by the excessive influx of calci...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.2.203

    authors: Cosman KM,Boyle LL,Porsteinsson AP

    更新日期:2007-02-01 00:00:00

  • The use of alpha-adrenoceptor antagonists in lower urinary tract disease.

    abstract::alpha-adrenoceptor antagonists have traditionally been used in the treatment of hypertension but in recent years they have become increasingly common in the treatment of benign prostatic enlargement (BPE), where they reduce the 'dynamic' component of bladder outlet obstruction and appear to have additional actions to ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.2.167

    authors: Chess-Williams R

    更新日期:2002-02-01 00:00:00

  • State-of-the-art pharmacotherapy for diabetic neuropathy.

    abstract:INTRODUCTION:The global epidemic of diabetes has led to an epidemic of diabetes complications. Diabetic neuropathy is the most common microvascular complication, of which diabetic peripheral neuropathy (DPN) and autonomic neuropathy (AN) are the most prevalent, affecting ~50% of patients. DPN results in pain with a poo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1812578

    authors: Azmi S,Alam U,Burgess J,Malik RA

    更新日期:2021-01-01 00:00:00

  • Advances in pharmacotherapy for hyperphosphatemia in renal disease.

    abstract:INTRODUCTION:Hyperphosphatemia in chronic kidney disease (CKD) is considered as an independent risk factor for surrogate clinical end points like vascular calcification (VC) and bone disease, or hard clinical outcomes like cardiovascular events. Various treatment options are available for phosphate removal or reduction...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1092521

    authors: Spasovski G

    更新日期:2015-01-01 00:00:00

  • Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.

    abstract:INTRODUCTION:Venous thromboembolism (VTE) causes substantial morbidity and mortality worldwide. The traditional treatment of VTE, with an initial therapy with (low molecular weight) heparin or fondaparinux and a continued treatment with vitamin K antagonists, is effective but has limitations. AREAS COVERED:The current...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.999043

    authors: Vanassche T,Vandenbriele C,Peerlinck K,Verhamme P

    更新日期:2015-04-01 00:00:00

  • Pharmacological management of transient synovitis.

    abstract::Synovitis is a painful and, occasionally, disabling disease. Patients with synovitis, especially new onset synovitis, should be referred to a rheumatologist urgently so that they can be assed and treated as quickly as possible. Clinical assessment and investigations are required to help differentiate between transient...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.1.35

    authors: Sokoll KB,Helliwell P

    更新日期:2006-01-01 00:00:00

  • Advances in chemical pharmacotherapy for managing acute decompensated heart failure.

    abstract:INTRODUCTION:Acute decompensated heart failure (ADHF) contributes largely to the burden of heart failure and is associated with a poorer prognosis. Although numerous clinical trials evaluated the benefit of newer medications for ADHF, most of them were not successful. Areas covered: This review focusses on the updates ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1299708

    authors: Yandrapalli S,Tariq S,Aronow WS

    更新日期:2017-04-01 00:00:00

  • Recent advances in the medical therapy of Crohn's disease in childhood.

    abstract::Crohn's disease (CrD) is characterised by an ongoing inflammatory response in the gut, in the absence of an obvious trigger. The treatment of CrD in children, during relapse and remission, requires special consideration of growth and development. This review addresses the use of present medical management strategies, ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.15.2553

    authors: Bremner AR,Beattie RM

    更新日期:2007-10-01 00:00:00

  • Palliative treatment of unresectable metastatic colorectal cancer.

    abstract:IMPORTANCE OF THE FIELD:Treatment options for metastatic colorectal cancer (mCRC) patients have rapidly increased in the past years, but 50 - 70% of mCRC patients are still unlikely to undergo radical resection of metastases and are candidates for palliative therapy only. AREAS COVERED IN THIS REVIEW:Oxaliplatin and i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903427997

    authors: Fornaro L,Masi G,Loupakis F,Vasile E,Falcone A

    更新日期:2010-01-01 00:00:00

  • Strategies in the treatment of HIV-1-associated adipose redistribution syndromes.

    abstract::HIV-1/highly active antiretroviral therapy-associated lipodystrophy syndrome (HALS) is presently the most common long-term adverse effect limiting the doubtless efficacy of antiretroviral therapy. It has a great impact on the quality of life of patients, it is stigmatising and its psychologically devastating consequen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.12.1871

    authors: del Mar Gutierrez M,Mateo G,Domingo P

    更新日期:2007-08-01 00:00:00

  • Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients.

    abstract:INTRODUCTION:Antifungal resistance is an emerging problem that increases morbidity and mortality in immunosuppressed pediatric patients, who suffer from invasive fungal diseases. Optimal pharmacological management is critical for the successful treatment of invasive fungal infections by resistant strains. AREAS COVERE...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1000302

    authors: Stergiopoulou T,Walsh TJ

    更新日期:2015-02-01 00:00:00